<DOC>
	<DOCNO>NCT00499850</DOCNO>
	<brief_summary>A Phase I , open label study assess safety tolerability ZD6474 combination 5-Fluorouracil , Leucovorin Oxaliplatin ( mFOLFOX6 ) first second line therapy patient advance colorectal adenocarcinoma .</brief_summary>
	<brief_title>Phase I FOLFOX Combination</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Histologically confirm locally advance , recurrent metastatic colorectal adenocarcinoma ( Stage IV ) 2. WHO performance status 01 3. one measurable lesion min 10mm spiral CT min 20mm conventional technique 1 . Brain metastasis spinal cord compression unless irradiate least 4 week entry stable 2. last dose prior chemotherapy discontinue least 4 week start study treatment 3. prior unanticipated severe reaction oxaliplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ZD6474</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>colorectal</keyword>
	<keyword>adenocarcinoma</keyword>
</DOC>